Navigation Links
Fat Screen Delivers Plant-derived Chemical With Antidiabetic Effects

After screening hundreds of compounds for their effects on fat development, researchers have discovered that an ingredient found in some plants fights diabetes in mice without some of the side effects attributed to other antidiabetes drugs.

The chemical they pinpointed, known as harmine, was first isolated more than 150 years ago from plants traditionally included in ritual and medicinal preparations around the world, the team reports in the May issue of the journal Cell Metabolism, published by Cell Press.

The work suggests a new approach for treating insulin resistance that might complement the use of preexisting drugs and, more generally, provides validation for fat cell screens as a promising strategy for identifying new metabolic drugs, according to the researchers.

While harmine itself has effects on the central nervous system that may preclude its use, "it may eventually be possible to separate the nervous system and metabolic effects of harmine through optimization of the chemical structure," said Peter Tontonoz, a Howard Hughes Medical Institute investigator at the University of California, Los Angeles. Harmine has been known to induce hallucinations, convulsions, and tremors.

The principal class of drugs prescribed for obesity-related diabetes, called thiazolidinediones or TZDs, work through a counterintuitive mechanism: they restore insulin sensitivity by activating a central promoter of fat tissue production called peroxisome proliferator-activated receptor (PPAR).

"The current explanation for this paradoxical mode of action is the idea that the body needs a place to store lipids," Tontonoz said. "If the body becomes less able to store lipids in fat, it may deposit in other tissues," where it can spur disease.

Despite their efficacy, the development and clinical use of TZDs is limited by adverse effects such as fluid retention, weight gain, congestive heart failure, liver toxicity, and p otential cancer risks, the researchers said. Therefore, alternative approaches to treating insulin resistance are needed.

The researchers speculated that other small molecules that promote fat tissue by distinct mechanisms could be candidates for novel insulin sensitizers. By running a technologically advanced screen of more than 500 bioactive compounds, the researchers found that harmine has such a positive effect on fat. The fat cells under examination were manipulated such that they literally lit up when fat-boosting PPAR became active.

Further study of harmine's effects in diabetic mice found that the chemical increases insulin sensitivity in a manner similar to, though more roundabout than, the predominant antidiabetes drugs. Rather than triggering PPAR directly, the chemical blocks a pathway that normally inhibits fat cells' production. "Harmine inhibits an inhibitor for a net positive effect on fat" that ultimately appears to restore insulin response without some of the side effects attributed to TZDs, Tontonoz said.

The findings provide "a second example of a small molecule that both promotes fat cell differentiation in vitro and improves glucose tolerance in vivo," Tontonoz's team concluded. The biological activities of harmine and TZDs underscore the fact that links between fat tissue and insulin resistance are complex and are likely to involve not only changes in fat tissue differentiation and cell number but also changes in the fat cells' function, they said.


'"/>




Related medicine news :

1. Screening device for ovarian cancer
2. Screening bypasses radical breast surgery
3. Screening of Lazy Eye
4. Screening Cost-Effective for Lung Cancer
5. Screening Newborns Questioned
6. Easier Methods Required to Screen Insulin Resistance
7. Easier Methods Required to Screen Insulin Resistance
8. Screening For Prostate Cancer in men over 75 Questioned
9. Ultrasound Screening Could Improve The Outcome Of Critically ill Patients
10. The Effectiveness Of Screening Tests Questioned
11. Screening Test For Early Diagnosis Of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/30/2016)... (PRWEB) , ... May 30, 2016 , ... ... to use inside of FCPX," said Christina Austin - CEO of Pixel Film ... for use within Final Cut Pro X. Choose from abstract transitions to more ...
(Date:5/29/2016)... ... 29, 2016 , ... Whole Health Supply is happy to announce a new ... available to the public. This is an unusual clipper because it opens to a ... , Everything about this product is concentrated on ease of use, functionality and durability. ...
(Date:5/28/2016)... ... May 28, 2016 , ... After a year and a half of planning the Multiple ... The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the ... United Kingdom came together to explore the many pathways individuals use to get into and ...
(Date:5/27/2016)... New Hampshire (PRWEB) , ... May 27, 2016 , ... ... skin care products, announced today that it has been recognized as one of the ... entering parenthood. Badger was named as one of nine small businesses providing progressive benefits ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... educate the many who are unaware of the plight of aphasia. In collaboration ... within the “Stroke Awareness” campaign. , The link between stroke and aphasia is ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... PUNE, India , May 30, 2016 /PRNewswire/ ... research report "Healthcare Analytical Testing Services Market by ... Monitoring, Bioanalytical Services), by End User (Pharmaceutical Companies, ... published by MarketsandMarkets, The market witnessed healthy growth ... grow at a CAGR of 11.3% between 2016 ...
(Date:5/30/2016)... , May 30, 2016 Eye expert ... of premature babies to seek an eye examination ... condition     Moorfields Eye Hospital Dubai, ... London , has identified premature babies as a ... because of their particular vulnerability to retinopathy of prematurity (ROP). ROP ...
(Date:5/27/2016)... 2016 Kitov Pharmaceuticals ... on late-stage drug development, today announced the completion ... pivotal batches required for registration of KIT-302 with ... follows Kitov,s announcement in December 2015, ... its primary efficacy endpoint. "We are ...
Breaking Medicine Technology: